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Introduction
Decades of successful clinical investigator effort have established 
modern management strategies for Hodgkin lymphoma (HL) 
which have led to improved patient outcomes. These risk-adap-
tive patient care strategies apply chemotherapy and radiation 
therapy (RT) determined by patient stage, volume of disease, risk 
of recurrence, response to induction therapy, and evaluation of 
risk for normal tissue outcome. Based on response to initial 
chemotherapy, future studies for patients of all age groups will 
further adapt therapy by adjusting the extent of chemotherapy 
and the use of RT. Despite the infrequent diagnosis of HL, 
cooperation between multidisciplinary investigators has led to 
increased patient enrollment on HL clinical trials in Europe and 
North America. This is important as the disease has an annual 
incidence of 2.4 cases per 100 000 people with 0.4 deaths per 
100 000 people. In other words, 0.2% of people will develop HL 
in their lifetime with approximately 85% of all patients surviving 
5 years from the initial diagnosis.1 Participation in clinical trials 
has served to significantly advance our understanding of treat-
ment and adjust management strategy in this rare and unique 
disease. Worldwide trials will help answer questions affecting 
subsets of the HL population in a timely manner.
Over the past several decades, European and North American 
clinical investigators have conducted multiple successful clinical 
trials in early-, intermediate-, and advanced-stage HL. As a 
result of patient participation on protocol, studies are now pow-
ered to answer important questions required for the practice of 
modern clinical oncology. It has been gratifying to recognize the 
willingness of investigators and patients participating in studies 
that are designed to answer challenging modern practice ques-
tions about the specific and increasingly important subsets of the 
HL patient population. Worldwide participation will become 
essential as biomarker development serves to further define the 
HL patient population subsets. These subsets include younger 
and older patients at diagnosis and those patients identified with 
unique evolving clinical features and biomarkers not yet fully 
characterized. As we personalize and tailor therapy in this rare 
and age-agnostic disease, we can ask more specific questions and 
adjust treatment to patient indication and response to induction 
therapy. Global study participation will be essential to meet more 
tailored study accrual objectives.
In this article, the current status of HL management in 
clinical trials will be reviewed and the status of current proto-
cols in Europe and the United States/North America will be 
discussed. Differences in management practice as well as areas 
of protocol alignment will be presented. Opportunities and 
strategies for clinical trial globalization will be explored.
Initial Medical Evaluation
The medical evaluation of patients has become more uniform 
between European and North American investigators. A medical 
history, including an evaluation of the presence or absence of B 
symptoms (constitutional symptoms including fever, night sweats, 
and weight loss of >10% of total body weight over 6 months), 
needs to be documented as well as other disease-related symptoms 
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such as fatigue, pruritus, and alcohol-induced pain. Chest x-ray 
and computed tomographic (CT) scan of the neck, chest, abdo-
men, and pelvis are mandatory studies. A baseline positron emis-
sion tomography (PET) may also be performed. Many clinical 
trials require PET scans. Because PET is very sensitive for bone 
marrow involvement, bone marrow biopsy is no longer uniformly 
required. If a PET study is not available, bone marrow biopsy is 
required. A complete blood count, erythrocyte sedimentation rate 
(ESR), and blood chemistries are required as are screening for 
hepatitis B and C and human immunodeficiency virus. A thor-
ough cardiopulmonary evaluation is required for patients at risk 
for acute/long-term complications. Reproductive counseling is 
important to both sexes. There is no disagreement on these points 
between European and North American study groups. 
International collaboration on the evaluation process is feasible as 
much of the workup is already agreed on by members of the inter-
national oncology community.
Staging and Eligibility
Staging has been relatively uniform between groups in Europe 
and North America. Stage I patients involve one nodal group 
and stage II patients involve more than one nodal group on the 
same side of the diaphragm. Stage III patients have nodal dis-
ease on both sides of the diaphragm and stage IV patients have 
parenchymal, bony, or visceral disease as defined on imaging. 
The A and B categories are also assigned to further describe 
the disease. Patients assigned as B have constitutional symp-
toms including fever, night sweats, and weight loss of >10% of 
total body weight over 6 months. The A category is assigned if 
the patient has no B symptoms.
To compare treatment strategies between groups, we need 
to assess and understand the differences in how patients are 
characterized for favorable/unfavorable early-stage status as 
well as define intermediate- and advanced-stage status. There 
are differences between individual European and North 
American groups. Defining unfavorable status for early-stage 
patients, the German Hodgkin Study Group (GHSG) and the 
National Cancer Institute’s (NCI) National Clinical Trials 
Network (NCTN) do not list specific age criteria. Patients 
≥50 years of age in the European Organisation for Research 
and Treatment of Cancer (EORTC) and ≥40 in the National 
Cancer Institute of Canada (NCIC) Clinical Trials Group are 
defined as unfavorable. An ESR of >50 for A patients and >30 
for B patients for the GHSG and the EORTC and an ESR of 
50 or any B symptoms in the NCIC and NCTN define unfa-
vorable status. A mediastinal mass ratio of >0.33 defines unfa-
vorable status for the GHSG and the NCTN. The NCIC 
defines a ratio of 0.33 or size >10 cm as unfavorable and the 
EORTC defines a mediastinal mass ratio of 0.35 as unfavora-
ble. Three or more nodal sites for the EORTC, NCIC, and the 
NCTN and more than 2 sites for the GHSG are assigned to 
unfavorable status. The GHSG also assigns unfavorable status 
to patients with any extranodal site of disease. Mixed cellularity 
and lymphocyte-depleted histology define unfavorable status 
for the NCIC and any site >10 cm defines unfavorable status 
for the NCTN. As can be seen, a thorough understanding of 
the definitions of HL is required to make certain that specific 
patient groups can be compared in different studies. These dif-
ferences should be considered relatively modest in nature and 
with international collaboration; common ground can likely be 
achieved in establishing worldwide clinical trials. In the 
National Institutes of Health (NIH) registry of clinical trials 
(ClinicalTrials.gov), there are more than 200 institutions out-
side of the United States that participate in clinical trials; 
therefore, reaching closure on common platforms for analysis 
this objective is within our grasp.2
History of Clinical Trials in HL
Sir Thomas Hodgkin in 1832 is credited with the initial 
description of HL when he reported on a series of patients 
with enlarged lymph nodes and splenomegaly which appeared 
quite different from other known diseases at that time. Toward 
the end of the 19th century, pathologists working in the 
United States and Germany (Dorothy Reed and Carl 
Sternberg) identified many of the classic initial descriptions of 
the disease, and the recently discovered x-rays were applied to 
successfully treat enlarged lymph nodes. The introduction of 
the modern linear accelerator and the development of a 4-drug 
chemotherapy model at the NCI known as MOPP (mechlo-
rethamine, oncovin, procarbazine, and prednisone) began a 
series of clinical trial models that led to successful patient 
treatment programs.3 The initial programs had protracted 
therapy following successful first-line therapy models for 
childhood and adult leukemia. European investigators intro-
duced ABVD (doxorubicin, bleomycin, vinblastine, and dacar-
bazine) to attenuate chemotherapy-associated side effects of 
management and several European groups, including the 
EORTC and GHSG, began clinical trial investigations. The 
GHSG introduced a more intensive 7-drug regimen 
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine, and prednisone) with 
improved early response rates in patients with advanced dis-
ease coupled with more early toxicity and long-term sterility. 
This resulted in a dual and conflicted approach to modern 
management. Many European investigators argued for a more 
aggressive early chemotherapy approach in the management 
of very high-risk patients to maximize freedom from relapse 
at the possible expense of acute and long-term toxicity. North 
American investigators favored a more tailored chemotherapy 
approach and reserve additional chemotherapy for patients 
who progressed despite initial management. With improved 
response rates and cure with chemotherapy, RT has been stra-
tegically used in clinical studies. Further improvements in 
diagnosis, including more precise definition of the tumor tis-
sue, have been recognized with the application of immuno-
logic markers. After more than 100 years of investigative 
science, investigators have confirmed the B-cell origin of HL. 
These efforts have been promoted by single investigators and 
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clinical group processes covalidated by collaborative investiga-
tion and clinical trials worldwide.
Although many process improvements are provided by indi-
vidual investigators, anatomic and metabolic diagnostic imag-
ing tools, immunopathology, enhanced disease characterization, 
and improved therapy technology, meaningful progress in stra-
tegic clinical management has been made by participation in 
clinical group protocol activity. Moving forward, cooperative 
multigroup protocols will be required to answer important 
questions including patient-specific tumor control and normal 
tissue outcome. In this effort, investigators set aside personal 
practice preferences and commit to common protocols to 
answer important clinical trial questions. Given the rare occur-
rence of the disease, management issues, including duration 
and intensity of therapy, can be addressed and long-term out-
come questions can be answered. Both the European Union 
and the United States/North America groups have had signifi-
cant success in conducting HL clinical trials which reflects the 
changes in strategy for patient care.4
HL Clinical Trials: United States and North America
Early cooperative group HL studies largely centered in the 
pediatric groups permitted adolescent and young adult partici-
pation. Often these studies treated patients with extended 
cycles of chemotherapy and large-volume RT reflecting the 
enthusiasm of initiating and maintaining response to therapy. 
Investigators were less cognizant of the effects of management 
on normal tissue and priority was placed on tumor control. In 
this era, more therapy was considered more optimal than less 
therapy. The Pediatric Oncology Group (POG) protocol 8725 
evaluated what would be called today, intermediate-, early-, 
and advanced-stage patients with HL. Patients were treated 
with 8 cycles of hybrid MOPP-ABVD chemotherapy. 
Following completion of chemotherapy, the patients were ran-
domized to receive RT to sites of disease defined on imaging at 
presentation or observed. Radiation right-left lateral volume 
attenuation was permitted in the mediastinum to limit dose to 
pulmonary parenchyma, whereas all sites of disease at presenta-
tion required postchemotherapy RT. At 5 years, there was no 
apparent added benefit to the addition of RT.5 However, more 
than 30% of patients treated with RT on study had volume 
deviations, specifically indicating that not all areas of disease at 
presentation were treated per study guidelines or included in 
the treatment fields. If those patients receiving RT per protocol 
were compared with patients receiving chemotherapy alone, 
the survival of those treated with RT was improved by 10% 
which was statistically significant (Table 1).6 This indicated 
that RT plays an additive role to chemotherapy but only when 
applied using a uniform standard. As the additive benefit was 
10%, this also implied that a large number of patients were suc-
cessfully treated with chemotherapy alone. If the patients who 
would not perform well with chemotherapy alone could be 
identified, then selected patients could be treated with RT. 
Further review of the 8725 data found that when RT was 
applied not in accordance with protocol guidelines, there 
appeared to be no added benefit to patients treated with 8 
cycles of hybrid chemotherapy. It is important to acknowledge 
this point when we establish an argument supporting the use of 
modern RT in this disease. This study opened the question of 
evaluating the role of real-time interventional quality assurance 
in RT to improve protocol compliance and strengthen study 
analysis. Deviation rates of 30% would not permit important 
study questions to be answered in a rare disease and efforts 
were made to address this issue as part of cooperative group 
study participation.
This study led to a series of risk-adapted protocols evaluat-
ing reduction in therapy in early- and intermediate-stage 
patients. Children’s Oncology Group (COG)/POG protocol 
9426 evaluated the role of response-adapted chemotherapy in 
early-stage patients with only 2 cycles of doxorubicin, bleomy-
cin, vincristine, and etoposide chemotherapy given to patients 
who achieved a rapid early response (RER) using anatomical 
and metabolic (gallium) imaging followed by 25.5 Gy to sites 
of original involvement with disease. Patients deemed slow 
early responders (SERs) received an additional 2 cycles of 
chemotherapy followed by 25.5 Gy. Real-time central review 
was used to ensure compliance. The study demonstrated no 
difference in survival between the groups suggesting that 
reduced therapy can be selectively applied to early-stage 
patients with favorable response to initial chemotherapy. The 
COG protocol 9425 evaluated ABVE-PC (doxorubicin, bleo-
mycin, vincristine, etoposide, prednisone, and cyclophospha-
mide) for 3 or 5 cycles based on initial response to chemotherapy 
with 21 Gy delivered to all sites of disease at presentation in 
patients with intermediate risk factors. Highly favorable out-
comes were seen in both protocols including the addition of 
adolescents and young adults as study participants prompting 
further investigation into reduction in chemotherapy and RT 
based on response to initial treatment in more advanced-stage 
patients. In both studies, there was significant improvement in 
protocol compliance with respect to RT using pretherapy 
review of RT data; however, interestingly, there was a signifi-
cant discrepancy in determining response between site and 
Table 1. Pediatric Oncology Group protocol 8725 survival according to 
treatment.a
TREATMENT 5-y RELAPSE-FREE 
SURvIvAL, %
Arm 1: chemotherapy alone 85
Arm 2: chemotherapy + radiation 
therapy
 
 Appropriate volume 96
 Major and minor deviations 86
Relapse-free survival indicating significantly better results when the radiation 
therapy was in accordance with protocol specifications.
aOnly patients who were in complete remission at the end of chemotherapy.
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study investigators as defined by both anatomical and meta-
bolic imaging reflecting the need for central review of imaging 
objects to make certain that there was uniformity in response 
assessment (50% discordance). At this time, the Children’s 
Cancer Study Group (CCG) performed a study randomizing 
the use of RT in patients with HL similar to POG 8725 and 
found that the use of RT improved event-free survival at 
10 years (91.2%/82.9%, P = .004) with no statistical benefit to 
overall survival validating previous CCG studies.7–10
In 2000, the 4 pediatric groups, POG, CCG, Intergroup 
Rhabdomyosarcoma Study Group (IRSG), and the National 
Wilms Tumor Study (NWTS) Group, merged to form the 
COG. This enabled increased accrual to studies with common 
objectives and introduced risk and response adaptive strategies 
as secondary points of randomization. Protocol AHOD0031 
evaluated intermediate-risk patients with risk-adaptive evalua-
tion using anatomical and metabolic imaging after 2 cycles of 
ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, 
prednisone, and cyclophosphamide). Patients who were 
deemed to have an RER received 2 additional cycles of chemo-
therapy and were reevaluated. Those who had a complete 
response (CR) were further randomized to no RT or 21 Gy RT 
to involved-field RT (IFRT). Patients with <CR received 
IFRT.11
The SERs were randomized to receive 2 additional cycles of 
ABVE-PC with or without 2 cycles of dexamethasone, etopo-
side, cisplatin, and cytarabine (DECA) chemotherapy. 
Involved-field RT was given to all SER patients. The results 
again were positive with no difference in survival at 4 years 
between the RER and SER patients. Event-free survival for 
RER patients with CR was not statistically improved with RT 
(87.9%/84.3%, P = .11) and not statistically different for the 
SER patients receiving/not receiving additional DECA 
(79.3%/75.2%, P = .11). However, for SER patients who were 
PET positive at the time of secondary randomization, there 
was a benefit (P = .05) to those who received additional DECA 
(70.7%/54.6%) implying the need for intensive therapy in this 
group of patients. All SER and RER patients in partial response 
after 4 cycles were treated with IFRT. The trial demonstrated 
the continued impression that early response assessment sup-
ported the use of therapy titration and/or augmentation with 
favorable patients receiving compressed treatment and unfa-
vorable patients receiving more prolonged treatment. In this 
study, there was central review of imaging and RT objects to 
assure uniformity in interpretation of response and to make 
certain that the RT was delivered per protocol.12–14
The success of these studies has prompted similar investiga-
tions into subsets of patients with HL including very-limited-
stage young patients and patients with advanced stage at 
presentation. As we begin to study smaller and more clinically 
specific subsets of patients, international participation will be 
essential to power studies appropriately for outcome analysis. 
These include assigning young patients with excised lymph 
nodes and no residual disease to observation. Advanced-stage 
patients would be assigned to extended chemotherapy and RT 
to original sites of bulk disease and sites which demonstrate a 
more limited response to chemotherapy. These protocols are 
designed to tailor therapy to the patient and balance the need 
for disease control and normal tissue outcome. Quality assur-
ance will be essential to answer important study questions in 
these subgroups of patients. It is important that the patient 
eligibility is confirmed and all the protocol-required data ele-
ments are available to investigators for primary and secondary 
study analyses.
In the United States/North America, there has been a dis-
tinction between adult and pediatric cooperative groups. Thus, 
HL clinical trials have been developed through both pediatric 
and adult prisms and have differences in management.11,15 In 
2014, the NCI transitioned its clinical trials system, the 
Cooperative Group Program, to the NCTN.16 Within the 
NCTN, the adult protocols conducted through Alliance for 
Clinical Trials in Oncology, SWOG, and ECOG-ACRIN 
have made contributions to our understanding of the disease 
and disease management. In the adult group studies, efforts 
have evaluated intermediate- and advanced-stage patients with 
emphasis on chemotherapy. Recent studies evaluate the role of 
adaptive therapy with PET to adjudicate secondary therapy 
pathways similar to the COG intermediate-risk protocol. 
Alliance/CALGB protocols 50604 and 50801 evaluated 
chemotherapy attenuation and continuation with and without 
RT and response assessment using PET.17–19 ECOG 2496 
evaluated the Stanford 5 regimen with ABVD and RT deliv-
ered to the mediastinum (bulk) in all patients.20 The patient 
study group for ECOG 2496 had intermediate- and high-risk 
features. The study demonstrated no benefit to more compre-
hensive chemotherapy and it is important to acknowledge that 
not all sites of involvement were treated with RT in these 
patients. SWOG 0816 likewise used PET in the evaluation of 
intermediate- and advanced-risk patients’ therapy adjustment 
based on response to PET. All patients in this study had stage 
III and IV HL.21 Most of the adult groups in the NCTN 
including the Aids Malignancy Consortium participated in 
this trial that evaluated an interim PET study after 2 cycles of 
ABVD chemotherapy. If the interim study was negative 
(Deauville 1-3: 82% of the study population), patients were 
then treated with an additional 4 cycles of ABVD. If the study 
was positive after 2 cycles (18% of the study population), the 
patients received 6 cycles of escalated BEACOPP. Of those 
who were PET positive after 2 cycles of ABVD, 11 of 60 
patients declined to switch to BEACOPP. The 2-year progres-
sion-free survival for PET-negative patients was 79% and for 
the PET-positive patients was 64%. Not unexpectedly, both 
hematologic and nonhematologic toxicities were greater in the 
BEACOPP group. Although the authors comment on the 
improvement in outcome, there is also opportunity for contin-
ued process improvements to further optimize patient out-
come. The currently active COG protocol AHOD1331 treats 
all patients with 5 cycles of ABVE-PC chemotherapy with/
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without brentuximab vedotin for advanced HL and is using 
consolidation RT to areas of limited response and bulk medi-
astinal disease at presentation with incremental boost RT to 
areas that remain PET active after cycle 5.22 In the GHSG 
HD15 trial, providing RT to areas of limited response in 
advanced-stage HL occurred in 11% of the patient population. 
In the current open advanced-stage COG trial, the number of 
patients receiving RT will be significantly higher because bulk 
mediastinal disease at presentation is a criterion for postch-
emotherapy RT.23
For the NCTN Network Groups in the United States and 
North America, the segregation of protocols between the 
COG and the adult groups has led to an interesting and unfor-
tunate dichotomy for the adolescent patient.11,15 These patients 
are treated in a different manner depending on whether they 
receive care from a pediatric or an adult medical oncologist. 
Pieters et al24 skillfully detailed the differences in treatment for 
the adolescent between the pediatric and the adult protocols 
including normal tissue volume with consolidation RT. The 
paper articulates differences in management including longer 
duration of chemotherapy and potentially wider-volume RT 
when applied in adult group protocols. Efforts to reconcile this 
issue to date have not been successful within the NCTN, and 
although a pediatric/adult integrated trial is currently active for 
soft tissue sarcoma, there has yet to be a hybrid trial in the 
United States and North America that includes all patients on 
a single study in an age-agnostic manner like European col-
leagues. The current status quo will be rate limiting when trials 
evaluating subsets of patient population. In comparison, this is 
the strength of the clinical trials conducted by European allies 
who evaluate patients with HL in a more age transparent 
manner.
HL Clinical Trials: European Union and GHSG
Many outstanding and pivotal studies have been completed by 
European investigators. Groundbreaking work was completed 
by Bonadonna and colleagues25 with the introduction of 
ABVD for clinical care. This served to limited acute toxicity 
and late effects from management and prompted a new gen-
eration of clinical trials using ABVD alone for early-stage dis-
ease and strategies using hybrid chemotherapy for patients 
with intermediate and advanced risk factors. The contributions 
have led to important process improvements in patient care.
In 1978, the GHSG was established. The administrative 
structure provides support for clinical trial activity including 
data acquisition and data management. The objective was to 
develop HL studies that were timely and addressed important 
questions of the day. To date, GHSG has developed 18 primary 
studies and several additional studies that have addressed issues 
with refractory and recurrent disease. The initial studies 
included early-, intermediate-, and advanced-stage patients 
and carefully evaluated multiple chemotherapy programs and 
options in the strategic application of RT to varied target dose 
and volume. As the group matured, protocols were designed to 
specific subgroups. There have been many notable and impor-
tant publications by this group. In protocol HD7, the GHSG 
confirmed the importance of chemotherapy in early-stage dis-
ease. Patients treated with chemotherapy (ABVD) and RT had 
improved freedom from treatment failure than those treated 
with RT alone (88%/67%). Protocol HD8 established that 
consolidation IFRT in early-stage patients with unfavorable 
features was as effective as and less toxic than extended volume 
RT. In HD9, COPP-ABVD, standard dose BEACOPP, and 
escalated dose BEACOPP were evaluated in patients with 
advanced-stage disease. The freedom from failure rate was 
69%, 76%, and 87%, respectively, statistically favorable to esca-
lated BEACOPP with uniform overall survival in all groups. 
This study shifted the discussion to an important area. 
Although there was greater toxicity with dose-escalated 
BEACOPP (increased etoposide), should we accept a poten-
tially lower primary control rate understanding that (1) patients 
could be rescued with additional therapy and (2) toxicity may 
be lower for patients not receiving extended chemotherapy. 
The protocol raised fundamental questions concerning the 
dilemma between toxicity and tumor control and established a 
series of protocols evaluating the role of BEACOPP in several 
protocols. HD11 did not establish that BEACOPP and 20 Gy 
RT were better than ABVD and 30 Gy RT in patients with 
early-stage disease with unfavorable features, therefore chal-
lenging the role of more intensive chemotherapy in this cohort 
of patients and maintaining that 30 Gy RT was preferable to 
20 Gy RT in this setting. The COG trials currently use 21 Gy 
RT. Reducing toxicity and maintaining efficacy in advanced-
stage HL were the objectives of HD12 with reduction in 
BEACOPP after 4 cycles of escalated BEACOPP. The results 
were sobering because toxicity was not improved and efficacy 
decreased, again suggesting that intensification of therapy was 
an advantage for disease control with the continued expense of 
toxicity despite dose reduction. Intensification with 2 cycles of 
BEACOPP and 2 cycles of ABVD plus 30 Gy RT was supe-
rior to ABVD plus 30 Gy RT for early unfavorable patients in 
HD14. There was more toxicity with intensification, however, 
no increase in mortality and second malignancies. HD15 intro-
duced PET-guided therapy for advanced-stage patients and 
evaluated 8 versus 6 cycles of dose-escalated BEACOPP with 
RT applied to areas of limited response based on anatomical 
and metabolic imaging. About 11% of patients received RT on 
this trial. Six cycles were compared favorably with 8 cycles, and 
the negative predictive value of PET was 94%. The study solid-
ified the impression that chemotherapy dose escalation was 
superior but the number of cycles could be reduced and not 
compromise outcome using PET as a tool to adjudicate the 
approach.22,23,26–31
The GHSG has excellent processes in place that can acquire 
protocol information including imaging and RT objects simi-
lar to quality assurance offices in the United States. The GHSG 
studies have included therapy attenuation for early-stage 
patients and patients with early response to treatment who 
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have more advanced disease at presentation. Early studies sup-
ported the use of RT as consolidation treatment and over time 
demonstrated the advantage of decreasing the RT volume and 
dose, based on response and disease location at presentation. 
More recent studies have adjusted the application of RT to 
specific areas of limited response and bulk at presentation. This 
concept is under evaluation in North American clinical trials as 
well.
These concepts were likewise supported in part by a recent 
study completed by fellow European colleagues32 evaluating 
the use of ABVD and BEACOPP 4 × 4 in patients with inter-
mediate and advanced risk features. The study demonstrated 
findings similar to GHSG investigators that ABVD and dose-
adjusted BEACOPP for etoposide demonstrated no clear 
advantage to de-escalated BEACOPP. The data treating 
patients with dose-escalated BEACOPP in the GHSG with 6 
cycles of escalated therapy with/without RT remain the strong-
est information to date for freedom from failure. There may, 
however, be no increase in overall survival as those who fail 
primary management to date respond to secondary therapy. 
The objectives of the studies between the United States and 
the GHSG are asymmetric as the US studies generally began 
treatment with ABVD with attenuation or intensification 
driven by response to treatment. The German group estab-
lished the paradigm to initiate care in advanced-stage patients 
with more intensive therapy with dose/therapy adjustment to a 
less-intensive regimen if the patient achieved a good response 
to initial management. The GHSG investigators demonstrated 
improved CR and event-free survival rates with more intensive 
initial therapy and as a consequence established a strategy to 
limit first-course failure perhaps at the expense of toxicity. 
American and some European investigators suggest that 
because patients can be rescued with secondary/relapse therapy, 
achieving up-front full CR at the expense of toxicity remains 
less desirable.33–35 Table 2 summarizes Hodgkin studies.
Assignment of Risk
There are differences between the United States and European 
investigators in the assignment of risk in protocols. Investigators 
agree on low-risk patients with favorable features. These gen-
erally include patients with stage I and II disease, A status, and 
no bulk. Patients with stage I and II disease with bulk and 
selected other features including mixed cellularity histology are 
often classified as early-stage unfavorable patients in GHSG 
and European protocols and as intermediate-risk patients in 
protocols generated in the NCTN/North America. 
Intermediate-risk patients include stage I and II patients with 
B symptoms and bulk as well as stage III and IV patients with 
A symptoms. Advanced-stage III and IV patients include 
those with bulk and B symptoms for groups in the United 
States/North America and Europe. There remains a challenge 
in overlap areas between groups and we will need to be careful 
in reviewing publications, understanding that there may be dif-
ferences in clinical trial populations within specific groups.
Influence of Imaging on Clinical Trials in HL
Imaging is an integral component to clinical trials and there is 
no other disease where imaging has had a larger impact on 
clinical trial management. Imaging has influenced staging and 
compressed the time from diagnosis to initiating treatment. 
The CT and PET are the primary vehicles used for determin-
ing response which generate secondary and tertiary points of 
randomization. The ease of secure image transfer through mul-
tiple digital media formats has facilitated this. Web-based tools 
enable study and site investigators to review imaging in real 
time.
Historical image interpretation by site investigators was 
accepted as the standard for trial management. The COG pro-
tocol 9426 established the fact that there can be a significant 
difference in site and central interpretations of response which 
can obscure trial results. Study groups in North America and 
Europe are now routinely place high importance on imaging, 
embedding imaging in clinical trials for staging, defining and 
adjudicating response, and assessing treatment failure.
With the ease of digital data transfer, the international 
treatment community is provided with a rare opportunity to 
integrate clinical trial strategies and collaborate in a manner 
previously impossible to achieve. Of equal importance, qual-
ity assurance centers recognize that image quality is improv-
ing worldwide, imaging colleagues are performing volumetric 
CT imaging and PET studies with the timing and vigilance 
required by protocol, and imaging acquisition strategies are 
well established. This has changed clinical trials manage-
ment, permitting real-time central review with site and study 
investigators. This permits harmonization of interpretation 
of response and ensures that the patient is assigned to the 
correct protocol and that response to therapy is interpreted 
in a uniform manner. Disease recurrence/progression can be 
done in a collaborative manner, and all important decisions 
that are essential for clinical trial management can be accom-
plished by consensus management. This harmonization will 
serve to facilitate international trial participation moving 
forward.
Early-Stage Favorable Patients
This group of patients has undergone extensive evaluation over 
the past several decades. Studies have demonstrated that ther-
apy titration driven by response is an acceptable therapeutic 
strategy for North American and European trial groups. We 
have evidence from these investigators that ABVD and alter-
native chemotherapy given in less than 4 cycles along with stra-
tegically limited volume RT is curative in most of the patients. 
International collaboration will help us evaluate different and 
perhaps more limited chemotherapy agents and assess patterns 
of failure to better understand the role of local therapy in these 
patients. There is no fundamental disagreement between 
European and North American investigators on this point and 
international cooperation will permit study of this selected 
patient cohort.
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Early-Stage Unfavorable Patients
This is an important group of patients who have features at 
presentation that may appear less favorable. Patients who dem-
onstrate an excellent response to induction chemotherapy may 
benefit from therapeutic titration. Often these patients have 
stage I and II disease with bulk. European investigators have 
studied this population which has not been as visible in NCTN 
trials as these patients have uniformly been considered inter-
mediate risk. With an international trial, this subgroup could 
be made more visible, empowered by collaboration to meet 
accrual objectives and establish common pathways for trial 
management.
Intermediate-Risk Patients
In NCTN clinical trials, intermediate-risk patients often 
include patients who would otherwise be considered early-stage 
unfavorable patients in European trials. These patients are also 
excellent candidates for clinical trials that adjust therapy based 
on response similar to the intermediate-risk clinical trial COG 
AHOD0031. The recent EORTC and AHOD0031 trials have 
provided evidence that response to induction therapy can per-
mit therapy titration in this cohort of patients. This group gen-
erally includes patients with IIB disease and patients with stage 
III and IVA disease. European studies have shown that ABVD 
and de-escalated BEACOPP demonstrate similar results in this 
setting with RT. AHOD0031 demonstrated that patients who 
had an RER to 2 cycles of chemotherapy and a CR to 2 addi-
tional cycles as defined on response imaging appear to have an 
equally good outcome whether or not the patients underwent 
consolidation RT with data published at 3 years. The study also 
demonstrated an advantage to patients who underwent more 
extended and aggressive chemotherapy who were deemed an 
SER and were PET positive on response imaging. Therefore, 
this is a diverse group of patients which can be differentiated by 
biological response to treatment validated by response to treat-
ment using modern imaging tools. International protocols can 
be directed with multiple tiers of evaluation based on response 
to chemotherapy. This may prove to be a good strategy to expe-
dite completion of trials and permit further evaluation of 
patients with varied response to induction therapy including 
additional therapy to patients who do not exhibit a CR to 
chemotherapy treatment. Therapies can be further titrated 
based on rapidity of response or augmented as needed if the 
response to initial therapy is protracted. The group with more 
delayed response requires process improvements as freedom 
from failure remains less than those who respond more rapidly 
despite the augmentation of therapy. This would include new 
agents including those directed to CD30 and new biologic 
therapies similar to patients with high-risk disease.
High-Risk Patients
This patient cohort often has large and diffuse tumor burden at 
presentation including bone marrow and visceral disease and 
often has B symptoms. The most visible separation in practice 
strategy between colleagues in Europe and North America is 
seen in this group. Colleagues in the GHSG would initiate care 
with dose augmentation and potentially revisit dose reduction 
in chemotherapy based on response. North American investi-
gators would consider approaches to care that may invite dose 
intensification induction therapies in high-risk patients; how-
ever, most protocols would move forward with strategies simi-
lar to intermediate-risk patients with dose augmentation 
therapies based on response to treatment. The arguments are 
dose augmentation as initial therapy will decrease secondary 
treatment due to relapse. North American investigators will 
argue that survival rates can be improved by secondary therapy 
at the time of relapse therefore limiting toxicity to patients who 
do well with less-intensive induction therapy. Protocols can be 
developed to test this hypothesis. Even with initial dose escala-
tion, relapse rates need and can be improved and new biologic 
therapy including application of RT as in COG protocol 
AHOD1331 can be used to address disease progression rates. 
International clinical trial participation will serve to better har-
monize treatment strategies. We have important work to do in 
this cohort of patients as freedom from failure rates remain 
suboptimal especially in patients who do not respond to initial 
therapy.
Radiation therapy
The role of RT has evolved over time. Early phase manage-
ment gave relatively high-dose RT to extended volumes of tis-
sue in the initial effort to control tumor. As evidence of 
treatment-related complications and second malignancies 
became more visible, efforts at radiation dose/volume modifi-
cation and therapeutic titration became embedded in clinical 
trials in both Europe and the United States/North America. In 
patients with low-risk disease, both European and NCTN 
investigators have evaluated the role of decreasing cycles of 
chemotherapy with attenuated dose of RT directed to sites of 
disease at presentation as defined on imaging. Patients with a 
CR to chemotherapy may not require RT and this will be an 
important study point moving forward. Early- and intermedi-
ate-risk patients with CR to chemotherapy as defined by meta-
bolic imaging also may not require RT. It is now clear that 
when RT is applied to patients with favorable outcome, only 
the sites of disease at presentation need to be treated to a dose 
in between 20 and 30 Gy based on the clinical situation. Lower 
doses are generally applied to protocols originating in the 
COG and higher doses in the adult NCTN groups and the 
GHSG. Protocols in advanced-stage patients evaluate the role 
of RT directed to areas at presentation that do not fully respond 
to chemotherapy. The COG trials in this cohort of patients are 
including RT to sites of bulk disease at presentation (mediasti-
num) with dose augmentation to sites of persistent activity on 
PET after cycle 5 of chemotherapy. In European/GHSG pro-
tocols, approximately 11% of high-risk patients will receive RT 
to sites that do not fully respond to chemotherapy as defined 
10 Clinical Medicine Insights: Oncology 
on imaging. In the current COG advanced-risk patients, the 
percent of patients undergoing RT will be considerably higher 
as bulk disease at presentation is a criterion for treatment. 
Clinical trials will help answer these questions moving forward. 
As part of clinical trial design, the patterns of relapse will be 
important to study to best determine the value of RT in all risk 
categories.
Quality Assurance
One area of alignment between European and North American 
colleagues is quality assurance including RT. As previously indi-
cated, North American trial protocol POG 8725 evaluated 
patients with intermediate-, early-, and advanced-stage features 
with 8 cycles of hybrid chemotherapy including MOPP-ABVD 
with RT to all sites of original disease as the point of randomi-
zation. The data were reviewed in retrospect after treatment had 
been completed. The study deviation rate was 30% and all devi-
ations were due to nonprotocol coverage of disease sites at pres-
entation. Patients who received RT per protocol guidelines had 
a 10% survival advantage to those who received chemotherapy 
alone. Because data transmission tools were becoming more 
nimble with digital media, the next series of clinical trials in 
COG required real-time pretreatment review of treatment 
objects. This experience decreased the RT deviation rate to less 
than 5%. However, these protocols required adjustment in treat-
ment based on response and it was found that central review of 
objects disagreed with site review more than 50% of the time in 
a pre-PET era of clinical trials. AHOD0031 required central 
review of imaging and RT objects in real time to manage sec-
ondary and tertiary trial randomization. This trial successfully 
managed real-time review of objects in more than 1700 patients 
with data reviewed at multiple time points during the course of 
this important study. Similar experience was seen by the GHSG 
recognizing the importance of quality assurance in trial out-
come. If patients are not treated in a uniform format, the results 
of the trial can be deceiving as was seen in POG 8725. The 
GHSG likewise has carefully monitored quality assurance for 
RT in their portfolio of trials and have published information 
demonstrating that adjustments were required in RT treatment 
plans in more than 50% of patients on early- and intermediate-
stage protocols.27 There are protocols, however, where quality 
assurance may not play as crucial a role. As can be seen in POG 
8725, excluding areas of disease eliminated any advantage seen 
by RT. In the GHSG, advanced-stage protocol only selected 
areas were treated with RT and intentionally did not include all 
areas of disease at presentation. In this protocol, quality of RT/
compliance to recommendations did not affect trial outcome. 
Modern protocols are asking questions concerning the role of 
RT and what specific volumes and dose to treat based on 
response to initial therapy. Quality assurance will be important 
moving forward to see whether these unique questions can be 
addressed in a clinical trial format and will require central review 
in real time to make certain that treatment is applied per intent 
of the protocol.
Summary
As clinical trials have matured, patient management strategies 
between investigators in Europe and North America have 
become more aligned. Methods of staging have become more 
uniform. Because of near-immediate ability to transfer imaging 
and RT objects for central review, it is now feasible to easily 
manage HL clinical trials on a worldwide basis. Although 
there are differences in how patients are assigned into catego-
ries, investigators are aligned in therapeutic titration for favora-
ble patients with early and intermediate risk features who 
demonstrate excellent response to initial chemotherapy. The 
ability to have information reviewed on a real-time basis will 
permit specific subsets of patients to be evaluated. This would 
include clinical trials in the very-young and very-early-stage 
patients with single lymph node involvement that is fully 
excised and older patients whose medical comorbidities require 
nontraditional approaches to management. High-risk patients 
require more study. Outcomes for these patients remain subop-
timal with need for improvement, especially in patients with 
more limited response to initial therapy. Patient care in this 
subgroup continues to be asymmetric with GHSG investiga-
tors favoring more intensive therapy to limit relapse with North 
American and some European investigators favoring less-
intensive initial therapy with dose augmentation if patients do 
not respond well to initial care. International registries with 
shared quality assurance responsibilities housed within estab-
lished centers can function at an enterprise level to make cer-
tain that normal tissue tolerance and second malignancies are 
carefully tracked and correlated to the chemotherapy and RT 
treatment plan. It will also be important for the NCTN to 
align the adult and pediatric groups into single protocols and 
not separate groups for adults and children. As indicated, ado-
lescents are fragmented in their care with this approach and 
European colleagues do not have this point of distinction. 
Adolescents and adults are treated in an identical manner by 
European colleagues and aligning the NCTN into a single 
strategy for management of HL will help facilitate accrual and 
meet clinical trial objectives for specific subsets of patients. 
This strategy also would facilitate completion of trials with 
new therapies aligned with specific biomarkers for those 
patients who do not succeed with primary management. We 
now have an opportunity to improve the management of these 
patients, and moving forward with worldwide trials will greatly 
improve our understanding of this disease and enhance patient 
management.
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